He mentioned a switch twice, specifically pro 140 blocking

New Post Public Reply Private Reply Replies (0) Message Board
trding sjacobs26 #8248
495
He mentioned a switch twice, specifically pro 140 blocking ccl5( rantes) which is why I have been looking at rantes stuff. I believe he has found that switch allows drugs to work again and we know that switch turns on the cancer fighting ability.
It sounded to me he has been testing this, and is confirming these possibilities, which is why he is so excited about the potential. The drug comment made me think he might have even be confirming using those specific drugs, just a guess though.




35:47 it's about ccr5 on certain immune cells
35:51 that that control the tumor okay so
35:54 there's two eight billion dollar-a-year
35:56 drugs called opdivo and keytruda
36:00 made by Merck and BMS that bring back
36:03 your own immune system to fight off the
36:05 tumor but you know what happens after
36:08 three to six months they stopped working
36:10 why do they stop working well this whole
36:13 new wave of cells comes in to shut that
36:17 immune response off that's part of the
36:19 elegance of our body in controlling you
36:23 know a immune response gone awry right
36:26 but in cancer we want the immune
36:28 response to go awry right those immune
36:32 cells called T reg cells, that come in
36:34 and supposedly shut off the light switch
36:37 that opdivo and keytruda have turned back
36:40 on, express ccr5. So if we get pro 140 it
36:45 can block those cells from coming in and
36:48 shutting off the immune response that
36:50 you just spent two hundred thousand
36:52 dollars a year to bring back in the
36:54 patient it's a tremendous opportunity
36:56 this is a immuno oncology drug it is it
37:01 always has been
and you know it hasn't
37:04 come to the forefront until just
37:06 recently now that we have more
37:08 information on how this immune response
37:11 against tumors is is regulated the other
37:14 thing that pro 140 does is it
37:16 reprogrammed
37:17 a cell called a macrophage think of
37:20 pac-man that little guy that goes around
37:22 and gobbles up little things on the
37:24 computer game
37:25 well macrophages come and gobble up
37:28 tumor cells normally right but when
37:31 they're when they're blocked by CCL5
37:34 which is a protein made by t-cells they
37:38 don't go and gobble up the tumor cells
37:39 when you block with pro 140 those
37:43 macrophages are now active against the
37:45 tumor again so this is extremely

37:49 exciting immuno Oncology drug and you
37:53 know what I think the field is just
37:54 starting to realize it it's the
37:56 quarterback of cells moving in the body
37:59 to where they need to be and prolong for
38:02 taking control of that and now we have a
38:05 diagnostic that says this drug is going
38:07 to bind exactly

Read More: https://investorshangout.com/post/view?id=553...z5zobKIfcC

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

AEC Firms Revamp Strategies Amid Talent Tug-of-War

Updated Category News Views 3

The State of Compensation in AEC Sit back and chew on this—AEC firms are playing a whole new ball game when it comes to compensating their talent. FMI Corporation’s 2026 Compensation Trends Study is putting a spotlight on what really goes on behind the scenes in architecture, engineering, and construction firms. This is about more than just tossing some coin for a...

Continue Reading
HIMS Faces Class Action: Investors Eye Leadership

Updated Category News Views 3

Another Day, Another Lawsuit: Hims & Hers in Hot Water Here's the latest conundrum in the corporate world, folks. Hims & Hers Health, Inc. (NYSE: HIMS) is caught up in a class action lawsuit that could shake up the telehealth scene. Investors who found themselves knee-deep in losses during the class period from August 2025 to July 2026 might want to pay attention. The...

Continue Reading
Curaleaf Eyes Growth: Conference Signals Opportunities

Updated Category News Views 0

Curaleaf's Strategic Move: Getting in Front of Investors Here comes Curaleaf Holdings, stepping into the spotlight with their eye on increasing investor engagement. Announcing their participation in the ATB Cormark Capital Markets 2026 Fall Institutional Investor Conference, the folks at Curaleaf aren't just talking—they're putting their top brass under the lights. You...

Continue Reading
ITP Media's Bold Move: Ready for Asian Market Surge

Updated Category News Views 3

Pushing Boundaries: ITP Media Group Eyes Asia ITP Media Group isn't here to tiptoe around the media market; they're diving headfirst with the recent takeover of Heart Media Group. A bold move, some might say, in this volatile world of media mergers and acquisitions. But let's break down what this really means. A Strategic Bet on Luxury To start, ITP Media is beefing up...

Continue Reading
Veteran Suicide Prevention: The Urgency Behind CVN's Push

Updated Category News Views 3

Veteran suicide is a crisis staring us square in the face, with rates 60% higher than the general population. It's a grim reminder that the mental toll on those who've served is a deep chasm hard to bridge. Cohen Veterans Network (CVN) is stepping up to the plate with a new campaign dubbed 'Ask Anyway: Conversations to Save a Life'. This isn't just any awareness...

Continue Reading
Guardio's AI-Driven Cybersecurity Triumphs at $1.1B Value

Updated Category News Views 0

A New Chapter in Cybersecurity's Playbook Guardio just hit a milestone that'll make any well-seasoned investor sit up and take notice. Their recent $1.1 billion valuation, fueled by a fresh $40 million funding round, underscores a seismic shift in the consumer cybersecurity landscape. We're talking a lineup of some seriously smart money like Assaf Rappaport, co-founder of...

Continue Reading
TVEyes Archive+: Revolutionizing Media Intelligence

Updated Category News Views 3

TVEyes Archive+ Takes Media Intelligence to New Heights Dishing out another update here, folks. TVEyes, the media intelligence powerhouse, just kicked off something that's got the potential to change the strategic media game—they call it Archive+. This tool isn’t just plundering old tapes; we're talking nearly two damn decades worth of historical broadcasts and...

Continue Reading
Pulnovo's PADN System Revolutionizes PH-LHD Treatment

Updated Category News Views 0

Pulnovo's Breakthrough in Heart Disease Management When Pulnovo Medical rolled out the PADN-HF-PH trial results at the ESC Congress 2026, seasoned investors like me sat up and took note. The trial, hot off the presses in The New England Journal of Medicine, unveiled how Pulmonary Artery Denervation (PADN) is throwing a wrench into the gears of conventional treatment of...

Continue Reading
MemoryDriver Relaunches with Navigation Challenge

Updated Category News Views 2

MemoryDriver's Relight: A Blazing New Course in Brain Health Look at this: Evon Medics is back with a bang, and they're handing us more than just another mind-numbing app update. On September 15, they're flipping the switch on MemoryDriver, their revamped brain-training gig, with a national 'Beat the Clock' Challenge. It’s up for grabs, totally free, and full of...

Continue Reading
Mitrade EU Enhances Investor Safety with New Insurance

Updated Category News Views 3

Mitrade's New Insurance: A Safety Net? Mitrade EU is amping up its game with some fresh insurance perks that catch the eye. They're slapping on some extra insolvency protection for clients trading under their CySEC license. Now that sounds like a financial shield anyone would want. Basically, they're adding another layer to the basic regulatory protections, and without...

Continue Reading

Top 5 Most Recently Viewed Articles

Adverum Biotechnologies Awards Stock Options to New Hire

Updated Category News Views 170

Adverum Biotechnologies Makes Inducement Grants Adverum Biotechnologies, Inc. (NASDAQ: ADVM) has made headlines recently by announcing the grant of stock options to a new member of their team. This strategic move is part of Adverum’s 2017 Inducement Plan, which is designed to attract and retain top talent by providing equity opportunities that align the interests of...

Continue Reading
Vanguard's February 2025 ETF Cash Distributions Explained

Updated Category News Views 304

Vanguard's February 2025 ETF Cash Distributions Vanguard Investments Canada Inc. has announced important cash distributions for various Vanguard ETFs. According to the latest update, unitholders of record on March 3, 2025, will receive distributions on March 10, 2025. Understanding these distributions is vital for investors, as they can influence investment decisions and...

Continue Reading
JetBlue Offers Special Nonstop Flights to the Big Game in New Orleans

Updated Category News Views 315

JetBlue Announces Special Nonstop Flights for Sports Fans JetBlue (NASDAQ: JBLU) is excited to provide sports enthusiasts with an exceptional travel experience this game season. By launching limited-time nonstop flights from major hubs like Newark and New York’s JFK Airport to the vibrant city of New Orleans, JetBlue aims to accommodate hundreds of additional fans eager...

Continue Reading
Examining Super Micro's Challenges Amid Regulatory Scrutiny

Updated Category News Views 194

Super Micro Computer Inc. came under fire in 2024 when the US Justice Department launched an investigation into allegations made by a former employee. This probe isn't just a minor hiccup; it follows closely on the heels of Super Micro settling with the SEC for $17.5 million over prior accounting issues back in 2020. Traders weren't just watching from the sidelines—they...

Continue Reading
ONEOK's Commitment to Dividends Shows Strong Financial Stability

Updated Category News Views 151

ONEOK Declares Consistent Quarterly Dividend The board of directors at ONEOK, Inc. (NYSE: OKE) announced a quarterly dividend of $1.03 per share. This declaration remains unchanged from the previous quarter, leading to an annualized amount of $4.12 per share. This consistency highlights ONEOK's reliability and commitment to its shareholders. Dividend Payment Schedule...

Continue Reading